Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| KPRX | 8-K | neutral | 3/10 | Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affa | Sep 9, 2026 |
| TEVA | 424B5 | neutral | 5/10 | Teva is launching a multi-tranche debt offering of EUR and USD senior notes across five maturities (2032-2037), with pro | Sep 9, 2026 |
| OKYO | 6-K | neutral | 3/10 | OKYO Pharma filed a 6-K announcing participation at the Cantor Global Healthcare Conference (Sept 9-11, 2026) with a fir | Sep 9, 2026 |
| NBP | 6-K | neutral | 3/10 | NovaBridge Biosciences announced the appointment of Martin Dewhurst as an independent director and member of the Audit a | Sep 9, 2026 |
| PHVS | 6-K | bullish | 8/10 | Pharvaris announced overwhelmingly positive topline data from the CHAPTER-3 pivotal Phase 3 study of deucrictibant XR fo | Sep 9, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced FDA accelerated approval of Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for 1st- | Sep 9, 2026 |
| PYXS | 8-K | neutral | 3/10 | Pyxis Oncology appointed interim CEO Thomas Civik as permanent CEO and Chairman, replacing John Flavin who becomes Lead | Sep 9, 2026 |
| ENGN | 8-K | neutral | 5/10 | enGene reported Q3 2026 results with a net loss of $0.47 per share, which was a 17.5% beat vs the $-0.48 consensus, but | Sep 9, 2026 |
| CMND | 6-K | bullish | 5/10 | Clearmind Medicine announced Yale IRB approval to initiate patient recruitment for Parts B and C of its Phase I/II trial | Sep 9, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab A/S filed a 6-K convening an Extraordinary General Meeting on October 7, 2026, to seek shareholder approval of th | Sep 9, 2026 |
| KROS | 8-K | neutral | 4/10 | Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million development milestone p | Sep 9, 2026 |
| INBX | 8-K | bullish | 7/10 | Inhibrx reported Phase 2 data for INBRX-106 in 1L HNSCC, showing a 48.3% cORR vs 26.5% for pembrolizumab alone, with a m | Sep 9, 2026 |
| URGN | CLUSTER | neutral | 2/10 | Two UroGen Pharma insiders, the Chief Medical Officer and General Counsel, sold a combined $102K in open-market shares o | Sep 9, 2026 |
| NTLA | 8-K | bullish | 7/10 | Intellia Therapeutics announced FDA acceptance of its Biologics License Application (BLA) for lonvoguran ziclumeran (lon | Sep 9, 2026 |
| EVO | 6-K | neutral | 4/10 | Evotec SE announced the initiation of a Phase 1 clinical trial for JST-018, a monoclonal antibody cocktail targeting ort | Sep 9, 2026 |
| ISCO | 8-K | mixed | 6/10 | International Stem Cell Corporation completed the sale of its wholly-owned subsidiary Lifeline Cell Technology (LCT) to | Sep 9, 2026 |
| VNRX | S-3/A | bearish | 7/10 | VolitionRx filed Pre-Effective Amendment No. 2 to its S-3 shelf registration, registering an additional 10,006,360 share | Sep 9, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K reporting weekly share repurchase activity under its existing DKK 15 billion buyback pr | Sep 9, 2026 |
| BBOT | EFFECT | neutral | 4/10 | BridgeBio Oncology Therapeutics, Inc. (BBOT) received SEC effectiveness on September 8, 2026 for its shelf registration | Sep 9, 2026 |
| EDIT | EFFECT | neutral | 4/10 | Editas Medicine's S-3 shelf registration (File No. 333-298665) became effective on September 8, 2026. This allows the co | Sep 9, 2026 |
| SBFM | EFFECT | bearish | 6/10 | The SEC declared Sunshine Biopharma's S-1 registration statement effective on September 8, 2026, allowing the company to | Sep 9, 2026 |
| KURA | 8-K | bullish | 6/10 | Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for di | Sep 9, 2026 |
| MSLE | 6-K | neutral | 3/10 | Satellos announced the WHO-assigned International Nonproprietary Name (INN) 'forazapadin' for its lead Duchenne muscular | Sep 9, 2026 |
| CANF | 6-K | bullish | 4/10 | Can-Fite announced the publication of a peer-reviewed case report showing that its drug Namodenoson improved decompensat | Sep 9, 2026 |
| IXHL | 8-K | neutral | 4/10 | Incannex Healthcare provided a corporate update covering clinical progress, intellectual property, and a strong cash pos | Sep 9, 2026 |
| IRD | 8-K | bullish | 7/10 | Opus Genetics reported positive 3- and 6-month data from the low-dose Cohort 1 of its Phase 1/2 trial for OPGx-BEST1 in | Sep 9, 2026 |
| TYRA | 8-K | bullish | 6/10 | Tyra Biosciences announced positive initial Phase 2 data for oral dabogratinib in FGFR3-altered low-grade intermediate-r | Sep 9, 2026 |
| PYXS | 8-K | bullish | 6/10 | Pyxis Oncology announced positive updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and | Sep 9, 2026 |
| GLMD | 6-K | neutral | 4/10 | Galmed Pharmaceuticals rebranded to Eocene Ltd., changing its Nasdaq ticker to EOCN effective September 10, 2026, and te | Sep 9, 2026 |
| SER | 8-K | bullish | 6/10 | Serina Therapeutics announced that the Independent Safety Monitoring Committee completed its blinded review of Cohort 1 | Sep 9, 2026 |